Last reviewed · How we verify
Rivoceranib (Apatinib)
At a glance
| Generic name | Apatinib |
|---|---|
| Also known as | Apatinib mesylate, ATAN, apatinib tablets, YN968D1, AiTan |
| Sponsor | Zhongda Hospital |
| Target | Vascular endothelial growth factor receptor 2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Secondary malignant neoplasm of stomach
Common side effects
Key clinical trials
- Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma (PHASE1,PHASE2)
- SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer (PHASE2)
- PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy (PHASE2)
- Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer (PHASE2)
- AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (PHASE3)
- A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC) (PHASE2)
- Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib (PHASE2)
- A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rivoceranib CI brief — competitive landscape report
- Rivoceranib updates RSS · CI watch RSS
- Zhongda Hospital portfolio CI